FDA Approves First Immunotherapy Drug for Breast Cancer
MONDAY, March 11, 2019 -- The U.S. Food and Drug Administration has given its blessing to the first immunotherapy regimen for breast cancer.
The combination of immunotherapy (Tecentriq) and chemotherapy (Abraxane) was given accelerated approval for...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Abraxane | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Immunotherapy | Pharmaceuticals